

1 Emergence of neutralizing antibodies associates with clearance of 2 SARS-CoV-2 during HIV-mediated immunosuppression

3

4 Farina Karim^{1,2}, Mallory Bernstein¹, Zesuliwe Jule¹, Gila Lustig³, Janine-Lee Upton¹, Yashica
5 Ganga¹, Khadija Khan^{1,2}, Kajal Reedoy¹, Matilda Mazibuko¹, Katya Govender¹, Kershnee
6 Thambu¹, Nokuthula Ngcobo¹, Elizabeth Venter^{4,5}, Zanele Makhado^{4,5}, Willem Hanekom^{1,6},
7 Anne von Gottberg^{4,5}, Quarraisha Abdool Karim^{3,7}, Salim S. Abdool Karim^{3,7},
8 Nithendra Manickchund⁸, Nombulelo Magula⁹, Bernadett I. Gosnell⁸, Penny L. Moore^{3,4,5,10},
9 Richard J. Lessells^{3,11}, Tulio de Oliveira^{3,11,12,13}, Mahomed-Yunus S. Moosa⁸, Alex Sigal^{1,2,3}

10

11 ¹Africa Health Research Institute, Durban, South Africa. ²School of Laboratory Medicine and Medical
12 Sciences, University of KwaZulu-Natal, Durban, South Africa. ³Centre for the AIDS Programme of
13 Research in South Africa, Durban, South Africa. ⁴SAMRC Antibody Immunity Research Unit, School of
14 Pathology, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.
15 ⁵National Institute for Communicable Diseases of the National Health Laboratory Service,
16 Johannesburg, South Africa. ⁶Division of Infection and Immunity, University College London, London,
17 UK. ⁷Department of Epidemiology, Mailman School of Public Health, Columbia University, New York,
18 NY, United States. ⁸Department of Infectious Diseases, Nelson R. Mandela School of Clinical Medicine,
19 University of KwaZulu-Natal, Durban, South Africa. ⁹Department of Internal Medicine, Nelson R.
20 Mandela School of Medicine, University of Kwa-Zulu Natal, Durban, South Africa. ¹⁰Institute of Infectious
21 Disease and Molecular Medicine, University of Cape Town, Cape Town, South Africa. ¹¹KwaZulu-Natal
22 Research Innovation and Sequencing Platform, Durban, South Africa. ¹²Centre for Epidemic Response
23 and Innovation, School of Data Science and Computational Thinking, Stellenbosch University,
24 Stellenbosch, South Africa. ¹³Department of Global Health, University of Washington, Seattle, USA.

25

26 **To design effective vaccines and other immune interventions against a pathogen, it is**
27 **necessary to know which aspect of immunity associates with protection. We**
28 **investigated whether neutralizing antibodies associate with infection clearance in long-**
29 **term SARS-CoV-2 infection during HIV-mediated immunosuppression. We monitored**
30 **neutralizing antibody activity against SARS-CoV-2 over 1 to 2 years in five participants**
31 **with advanced HIV disease and delayed control of HIV viremia. These participants had**
32 **persistent SARS-CoV-2 infection ranging from 110 to 289 days which was associated**
33 **with low or undetectable neutralizing antibody responses. SARS-CoV-2 clearance was**
34 **associated with the emergence of neutralizing antibodies and occurred in two**
35 **participants before suppression of HIV viremia, but after some CD4 T cell**
36 **reconstitution. Vaccination only further increased neutralizing antibody levels in the**
37 **advanced HIV disease participants who achieved HIV suppression pre-vaccination.**
38 **During the prolonged SARS-CoV-2 infection we observed widespread evolution which**
39 **was particularly pronounced in one Delta variant infection. This resulted in high-level**
40 **escape from Delta-elicited neutralizing antibodies and a virus antigenically distinct**
41 **from both ancestral SARS-CoV-2 and Omicron XBB in hamster experimental infections.**
42 **The results offer new evidence that neutralizing antibodies associate with SARS-CoV-**
43 **2 clearance and argue that successful management of HIV may be necessary to curtail**
44 **long-term infection and evolution of co-infecting pathogens.**

45

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

46 Introduction

47 Neutralizing antibodies are a key correlate of protection against most viral infections^{1,2}. During
48 the Covid-19 pandemic, evolution of new viral variants reduced the ability of neutralizing
49 antibodies elicited by previous infection or vaccination to prevent new symptomatic infections,
50 although protection from more severe disease was generally maintained³. One possibility of
51 how SARS-CoV-2 variants arise is evolution during long-term infection in immunosuppressed
52 individuals⁴⁻¹⁶. Such evolution in immunocompromised hosts is not unique to SARS-CoV-2
53 and has been observed in influenza and salmonella infections^{17,18}.

54 Case studies of SARS-CoV-2 infections in immunosuppressed individuals show prolonged
55 infection and evolution of genomic changes in the SARS-CoV-2 spike protein associated with
56 escape from neutralizing antibodies¹³. Mutations outside of spike are also common and may
57 confer different functions^{19,20}. SARS-CoV-2 long-term infection and evolution happens in some
58 individuals who are immunosuppressed because of long-term uncontrolled HIV infection,
59 termed advanced HIV disease^{4-6,15}. Here, immunosuppression occurs because HIV infection
60 depletes CD4 T cells by a variety of mechanisms that include death of both HIV-infected²¹⁻²⁴
61 and uninfected bystander or incompletely infected cells²⁵⁻²⁹. Advanced HIV disease is defined
62 as a CD4 T cell count lower than 200 cells/microliter (a normal CD4 T cell count is about 1000
63 cells/microliter). This level of CD4 T cell depletion is known to result in vulnerability to multiple
64 pathogens. One example is *Mycobacterium tuberculosis*, one of the cardinal infections leading
65 to the death of people living with HIV (PLWH) in the pre-antiretroviral therapy (ART) era^{30,31}.

66 While there can be multiple reasons for immunosuppression^{7,16,32-34}, the number of people
67 globally with immunosuppression because of advanced HIV disease may be considerable. In
68 South Africa alone, the estimated number of PLWH is about 8 million³⁵. About 1 in 10 are
69 thought to meet the criteria for advanced HIV disease^{36,37} - an estimated 800,000 people.
70 Vaccination could potentially be a strategy to elicit a better immune response in people with
71 advanced HIV disease. However, for SARS-CoV-2, vaccines were reported to be less effective
72 at eliciting a neutralizing antibody response in PLWH with CD4 counts lower than 200
73 cells/microliter³⁸⁻⁴⁰.

74 We have previously reported one case where advanced HIV disease interferes with SARS-
75 CoV-2 clearance and leads to SARS-CoV-2 evolution (participant 27 in this study)^{4,5}. The virus
76 which evolved in this participant over 6 months gained immune escape from neutralizing
77 antibodies elicited by SARS-CoV-2 infection and Pfizer BNT162b2 mRNA vaccination. Here
78 we tracked SARS-CoV-2 infection in five participants with advanced HIV disease and failure
79 to adhere to ART, who eventually suppressed HIV viremia. All had prolonged SARS-CoV-2
80 infection. Clearance was associated with emergence of neutralizing antibodies. Among the
81 viruses we isolated from these participants, SARS-CoV-2 originating in a Delta variant
82 infection evolved the most antibody escape mutations and had high-level escape from Delta-
83 elicited neutralizing antibodies. However, it did not escape the current population neutralizing
84 antibody immunity to SARS-CoV-2.

85

86 Results

87 Advanced HIV disease leads to long-term SARS-CoV-2 infection and evolution

88 Five participants with advanced HIV disease and HIV viremia are described in this study. They
89 are part of an observational longitudinal cohort of SARS-CoV-2 infection in South Africa
90 numbering 994 participants, including 113 PLWH with a CD4 T cell count lower than 200
91 cells/microliter at enrollment (Table S1). Participant information was de-identified and
92 participants assigned numbers. The linkage between number and identifying information is
93 only known to the clinical team of the study. The five participants, whose de-identified numbers
94 were 27, 96, 127, 255, and 209, were between 20 and 50 years old and had a Covid-19
95 diagnosis date ranging from September 2020 to December 2021 (Table S2). All participants
96 were living with HIV before SARS-CoV-2 infection and participant 255 was HIV-infected by
97 mother-to-child transmission. Participants were outpatients for 82% of study visits. During
98 each study visit, a combined nasopharyngeal and oropharyngeal swab was taken to detect
99 SARS-CoV-2 by qPCR cycle threshold (Ct, Figure 1A) which is inversely proportional to
100 SARS-CoV-2 titer. The virus was isolated from the swab by outgrowth and/or sequenced when
101 viral titers were sufficient (Ct<30 for sequencing and Ct<25 for isolation). The timepoints and
102 titers of successfully sequenced samples are shown in Figure 1A as red circles. The duration
103 of SARS-CoV-2 infection, calculated as time from first diagnostic to last qPCR positive SARS-
104 CoV-2 test was a median of 207 days, and ranged from 110 to 289 days (Table S2). Four of
105 the participants were enrolled soon after diagnosis. One participant (255) was enrolled in the
106 study in December 2021 during the Omicron infection wave. However, a record of a positive
107 qPCR result for SARS-CoV-2 was present from September 2021, corresponding the Delta
108 variant infection wave (Figure 1A).

109 Participants were initiated on ART in line with current national guidelines and received
110 adherence counselling from the clinical team. The ART regimen used was the integrase
111 inhibitor dolutegravir (DTG), combined with the nucleotide/nucleoside reverse transcriptase
112 inhibitors tenofovir (TFV) and lamivudine (3TC). The five participants described here had
113 delayed control of HIV viremia (Figure 1B). Retrospective detection of ART levels in this group
114 by liquid chromatography coupled with tandem mass spectrometry showed non-adherence to
115 the DTG based regimen. Green bars in Figure 1B show the time when DTG started to be
116 consistently detected and Figure S1 shows study visits where DTG, TFV, and 3TC were
117 detected. Surprisingly, other antiretroviral drugs were also detected, possibly previously
118 initiated regimens (Figure S1, blue rectangles). The participants eventually adhered to DTG
119 based ART (Figure S1, green rectangles), leading to HIV suppression observed as a decline
120 in HIV viremia to below the threshold of assay detection (40 HIV RNA copies/mL) during the
121 study (Figure 1B).

122 Four of the participants were vaccinated with two doses of the Pfizer BNT162b2 mRNA
123 vaccine and vaccination times are shown as vertical dashed lines in Figure 1A-B. The fifth
124 (127) was vaccinated with only one dose because the participant developed synovial
125 inflammation in the wrists and hands 6 days post-first vaccine dose, a rare adverse event
126 associated with Covid-19 mRNA vaccines^{41,42}. The interval between doses approximately
127 followed the South African guidelines at the time of vaccination, which was 6 weeks, although
128 some variation occurred.

129 We next determined the infecting variant by sequencing. Alignment of sequenced SARS-CoV-
130 2 showed that, consistent with the infection date (Figure 1A), the participant designated 27
131 was infected with ancestral SARS-CoV-2 (Figure 1C, grey circles) and the participant

132 designated 96 was infected with the Beta variant (Figure 1C, purple circles). Participant 127
133 was initially infected with a Beta variant (Figure 1C, purple triangles) but the last sequence
134 was a Delta variant (Figure 1C, highlighted in red), likely a re-infection which occurred during
135 the Delta infection wave in South Africa. Participant 255 was infected with the Delta variant
136 (Figure 1C, blue circles), consistent with a continuous infection from the first positive
137 diagnostic test in September 2021. Participant 209 was infected with the Omicron BA.1
138 subvariant (Figure 1C, green circles), but the sequence from the last timepoint was an
139 Omicron BA.5 subvariant (Figure 1C, highlighted in red), likely a re-infection.

140 We next analyzed non-synonymous changes across the SARS-CoV-2 genome from each
141 sequenced timepoint per participant using the Stanford Coronavirus Antiviral and Resistance
142 Database (<https://covdb.stanford.edu/sierra/sars2/by-sequences/>). Three of the participants,
143 27, 96 and 255, had extensive non-synonymous changes in the circulating virus, while two,
144 127 and 209, had few changes but showed an abrupt shift in sequence consistent with re-
145 infection with a different variant or sub-variant (Figure S2). Both 27 and 255 had multiple
146 substitutions in the receptor binding domain (RBD) of the spike gene predicted to lead to
147 escape from neutralizing antibodies. These included E484K, K417T and F490S⁴³⁻⁴⁷ in the virus
148 from participant 27 and K417T, L452Q, A475V, and E484A⁴⁶⁻⁵⁰ in the virus from participant
149 255.

150 **Long-term SARS-CoV-2 infection clearance associates with emergence of neutralizing** 151 **antibodies**

152 To investigate the relationship between the neutralizing antibody response and SARS-CoV-2
153 clearance, we isolated and expanded at least one SARS-CoV-2 virus from each participant
154 and tested the neutralizing capacity of the participant's plasma against the autologous
155 outgrown viruses at the different timepoints post-diagnosis. Figure 2A shows SARS-CoV-2
156 viral titers through time for each participant up to and including the virus clearance timepoint,
157 where clearance was defined as two or more consecutive timepoints where SARS-CoV-2 is
158 undetectable (see Figure 1A).

159 The neutralization capacity of participant plasma was determined throughout this work by a
160 focus forming assay with the live virus isolates (Figure S3). To quantify the result, we present
161 the focus reduction neutralization test 50 value (FRNT₅₀), the inverse of the plasma dilution
162 required for 50% neutralization. Ongoing SARS-CoV-2 infection was correlated with low
163 FRNT₅₀ values at or below the level of detection (Figure 2B). Strikingly, in all cases, there was
164 a strong increase in neutralization capacity against the autologous viruses at SARS-CoV-2
165 clearance (Figure 2B, last timepoint in each graph). The absolute FRNT₅₀ value which was
166 associated with viral clearance varied between participants. In participant 96 it also varied
167 between virus isolates. In participant 255, who had undetectable neutralizing antibody levels
168 before SARS-CoV-2 clearance, the FRNT₅₀ value became detectable but remained relatively
169 low.

170 We examined the HIV viral load (Figure 2C) and CD4 T cell counts (Figure 2D) at each
171 timepoint per participant. While participants 27, 96, and 127 showed HIV suppression at
172 SARS-CoV-2 clearance, participant 209 did not have full suppression (Figure 2C, rightmost
173 panel) and participant 255 was unsuppressed, with an HIV viral load of about 10⁴ RNA
174 copies/mL (Figure 2C, panel second from right). Immune reconstitution measured in terms of
175 an increase in CD4 T cell counts occurred in every participant (Figure 2D), although CD4
176 counts remained at 100 cells/microliter or below for 4 out of 5 participants. Participants had a
177 gradual increase in CD4 count to the time of SARS-CoV-2 clearance. However, participant

178 255, who did not have a suppressed HIV viral load at clearance, showed CD4 T cell
179 reconstitution which plateaued at a timepoint where SARS-CoV-2 was not yet cleared (Figure
180 2D, second from right).

181 **Poor vaccine neutralizing antibody response in advanced HIV disease participants with** 182 **HIV viremia**

183 We investigated the neutralizing antibody response elicited by vaccination in the advanced
184 HIV disease participants and compared the response to participants, either PLWH or HIV
185 negative, who did not have immunosuppression (Tables S3-S4). All participants received the
186 Pfizer BNT162b2 mRNA vaccine.

187 We tested for neutralizing antibodies against ancestral virus, the Beta, Delta and Omicron
188 BA.1 variants, as well as anti-spike antibody levels, at baseline and after each vaccine dose
189 (Figure 3A). In the three participants with suppressed HIV at vaccination (27, 96, and 127),
190 there was an increase in neutralization capacity for all strains/variants tested after the first,
191 and if administered, second dose of the vaccine, and a similar increase in overall anti-spike
192 antibodies. In participant 127, who received only one vaccine dose, vaccine elicited
193 neutralization waned quickly, with neutralization capacity dropping approximately 10-fold in
194 about 4 months against all viruses tested. In participant 27, neutralizing antibodies to Omicron
195 BA.1 showed rapid waning (Figure 3A).

196 In participants 255 and 209, HIV viremia was present at vaccination (Figure 1B). Participant
197 255 cleared SARS-CoV-2 at the vaccine baseline visit, before vaccination was administered.
198 Participant 255 still had SARS-CoV-2 infection at vaccination (Figure 1A). Both 255 and 209
199 showed a poor initial response to the vaccine (Figure 3A). For 255, neutralization capacity
200 decreased to below limit of quantification after the first dose and remained at that level after
201 the second dose. For 209, neutralization capacity increased with time, but not at two weeks
202 post-vaccination, the first post-vaccination timepoint tested and expected peak of the
203 neutralization response to the vaccine (Figure 3A, right panel).

204 To compare our results to participants without advanced HIV disease who were also
205 previously SARS-CoV-2 infected, we tested the antibody neutralization response after each
206 vaccine dose in five participants with either suppressed HIV or who were HIV negative (see
207 Table S3 for participant details). These participants showed a relatively homogenous
208 response, with a large fold-increase post-first dose, usually followed by limited waning, then a
209 smaller fold-increase in neutralizing capacity post-second dose (Figure 3B).

210 Interestingly, we observed that anti-spike binding antibody levels mirrored well the neutralizing
211 antibody response to the different viral isolates. The exceptions were the two advanced HIV
212 disease participants with HIV viremia at vaccination. For participant 255, the first timepoint
213 post-vaccination showed a strong increase in anti-spike antibodies but not neutralization
214 capacity, and this was also observed for participant 209 (who also had uncleared SARS-CoV-
215 2) at the baseline visit before administration of the first antibody dose.

216 We quantified the response post-second dose in a larger group of previously infected
217 participants with no advanced HIV disease (Table S4), who were PLWH (n=10) or HIV
218 negative (n=16). This group included the control group of five participants with detailed
219 longitudinal samples described above. In all participants, we tested for neutralizing antibodies
220 against ancestral virus, the Beta, Delta and Omicron BA.1 variants (Figure 3C). The three
221 advanced HIV disease participants with ART suppressed HIV at the time of vaccination
222 showed a vaccine mediated increase in neutralization of all four viruses (Figure 3C, green

223 lines). In contrast, neutralizing antibody remained low against the four viruses in the two
224 advanced HIV disease participants with unsuppressed HIV (Figure 3C, red lines). Unlike the
225 responses of the advanced HIV disease participants with suppressed HIV, these responses
226 were distinct from the neutralizing antibody vaccine responses of the participants with no
227 advanced HIV disease.

228 **Low XBB.1.5-infection elicited cross-neutralization of ancestral and Delta-evolved** 229 **viruses in hamster infections**

230 The degree to which neutralizing antibody immunity elicited by infection with one virus strain
231 can cross-neutralize a second strain is a measure of the antigenic distance between them.
232 However, given that SARS-CoV-2 seroprevalence in South Africa was approximately 70%
233 pre-Omicron⁵¹, we could not use human sera to measure antigenic distance between recent
234 Omicron subvariants such as XBB and other strains as we would be unlikely to find XBB
235 infected individuals who were uninfected with earlier variants. We have therefore investigated
236 cross-neutralization of ancestral SARS-CoV-2, the Omicron XBB.1.5 subvariant, and two of
237 the evolved SARS-CoV-2 strains with the most antibody escape mutations (Figure 4A) in the
238 Syrian golden hamster experimental infection model. The two evolved viruses were the virus
239 evolved from ancestral SARS-CoV-2 in participant 27 after a 190-day infection (27-D190), and
240 the virus evolved from the Delta variant in participant 255 after a 237-day infection (255-D237).
241 Sixteen days post-infection, plasma samples from uninfected and infected animals were
242 tested against the autologous (infecting) virus as well as the three other viruses to determine
243 cross-neutralization (Figure 4B).

244 Plasma from uninfected animals did not neutralize any of the viruses (Figure 4C). Plasma from
245 infected animals most potently neutralized the autologous virus and cross-neutralized the
246 other viruses less well (Figure 4D-G). The animals not infected with Omicron XBB.1.5 did not
247 have a substantial cross-neutralization of XBB.1.5 (Figure 4D-F), and animals infected with
248 XBB.1.5 failed to develop a cross-neutralizing response to the other viruses tested (Figure
249 4G).

250 To better visualize the antigenic distances between the viruses, we used antigenic cartography
251 (Figure 4H) which maps the distances between multiple viruses and the sera elicited by their
252 infections⁵²⁻⁵⁴. Here, each square of distance corresponds to a 2-fold drop in neutralizing
253 capacity. Using this visualization, we observed that 27-D190 was antigenically close to
254 ancestral virus from which it evolved. In contrast, XBB.1.5 was antigenically far from all the
255 other viruses tested. The Delta evolved 255-D237 was antigenically distinct from both
256 ancestral SARS-CoV-2 and Omicron XBB.1.5.

257 **Evolved Delta variant escapes Delta but not Omicron XBB-elicited neutralizing** 258 **antibodies**

259 People were likely infected through the course of the pandemic with multiple SARS-CoV-2
260 strains/variants, and therefore their neutralizing antibody responses may have a different
261 pattern than those we observed in the singly infected hamsters. As we have previously
262 characterized the 27-D190 evolved virus^{4,20}, here we tested the Delta variant evolved 255-
263 D237 virus which had mutations predicted to result in immune escape from neutralizing
264 antibodies (Figure 4A). We tested this virus against plasma panels from participants infected
265 in the Delta, Omicron subvariant BA.1, and Omicron subvariant XBB infection periods in South
266 Africa (see Table S5 for participant details).

267 We first tested 255-D237 against plasma from participants infected with the Delta variant. We
268 observed that, relative to the Delta variant virus, the 255-D237 had over 18-fold lower FRNT₅₀
269 (Figure 5A), escape similar to Omicron BA.1 relative ancestral virus in participants vaccinated
270 with ancestral virus based vaccines⁵⁵. We then tested this virus against plasma from Omicron
271 BA.1 infected participants. As we reported previously, we found Omicron BA.1 elicited
272 neutralizing immunity to be relatively low⁵⁶. The 255-D237 evolved virus had a 6.5-fold escape
273 of neutralization relative to the Omicron BA.1 virus in this group, with some of the neutralization
274 values for 255-D237 falling below the threshold of quantification (Figure 5B).

275 We then proceeded to test 255-D237 against plasma from vaccinated participants with
276 breakthrough Omicron BA.1 infection. As we previously reported⁵⁶, the vaccinated/BA.1
277 infected group had stronger Omicron BA.1 virus neutralization as well as better cross-
278 neutralization of other variants compared to the unvaccinated group. We observed that
279 neutralizing antibody immunity in this group neutralized the 255-D237 virus to a similar extent
280 as the BA.1 virus (Figure 5C). Lastly, we tested against plasma from individuals infected during
281 the period when Omicron XBB subvariants were dominant in South Africa (from November-
282 December 2022, [https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-
283 cov-2-genomic-surveillance-update/](https://www.nicd.ac.za/diseases-a-z-index/disease-index-covid-19/sars-cov-2-genomic-surveillance-update/) accessed August 8, 2023). These participants are also
284 expected to have immunity from previous infections, including pre-Omicron variants. In this
285 group there was no escape of the 255-D237 virus relative to the XBB.1.5 subvariant (Figure
286 5D).

287 **Discussion**

288 Here we characterized five long-term SARS-CoV-2 infections in individuals with advanced HIV
289 disease who had HIV viremia upon study enrollment. We found that SARS-CoV-2 clearance
290 was associated with the emergence of a neutralizing antibody response in every case. Based
291 on vaccine trials, neutralizing antibodies are a known correlate of protection against
292 symptomatic SARS-CoV-2 infection². However, this study is, to our knowledge, the first to
293 demonstrate an association between the emergence of an antibody response and SARS-CoV-
294 2 clearance in long-term infection in a group of participants. The study has the limitation that,
295 despite the large number of participants followed in our cohort, the number of participants with
296 advanced HIV disease and persistent HIV viremia was small. The potentially key role of the
297 neutralizing antibody response in clearing SARS-CoV-2 which we found in this study is
298 consistent with observations that B cell depletion with rituximab leads to persistent SARS-
299 CoV-2 infection⁵⁷⁻⁶⁰.

300 We observed that the neutralizing antibody response did not need to be very strong to
301 associate with SARS-CoV-2 clearance, as demonstrated for participant 255. A related
302 observation was that SARS-CoV-2 was cleared despite HIV viremia being present. Incomplete
303 HIV suppression at SARS-CoV-2 clearance was also observed in participant 209. Some
304 reconstitution of CD4 T cell numbers occurred in all participants, including the HIV viremic
305 participants, prior to SARS-CoV-2 clearance. CD4 T cell reconstitution likely occurred because
306 of ART initiation, even if initiation was partial. Since T cell help is essential to generate an
307 effective antibody response⁶¹, this reconstitution may have led to the production of neutralizing
308 antibodies to SARS-CoV-2.

309 We found that the Pfizer BNT162b2 mRNA vaccine was effective in increasing binding and
310 neutralizing antibodies against SARS-CoV-2 variants in participants with advanced HIV
311 disease who had ART suppressed HIV viremia. It was not effective in the two participants in
312 whom HIV viremia was still present. This agrees with previous studies showing a less effective

313 neutralizing antibody responses to vaccines in individuals with low CD4 T cell counts³⁸⁻⁴⁰.
314 Therefore, vaccination in the absence of HIV suppression may not be an effective strategy to
315 increase immunity in people with advanced HIV disease.

316 Interestingly, while binding antibody levels tracked closely with neutralization capacity, the two
317 viremic advanced HIV disease participants showed instances where binding antibodies were
318 elevated without a rise in neutralizing antibody activity, perhaps because of a lack of
319 neutralization potency, which can be associated with poor B cell affinity maturation^{62,63}.

320 All advanced HIV disease participants evolved SARS-CoV-2 mutations in their circulating
321 viruses in long-term infection. Two of the participants, infected with ancestral and Delta variant
322 viruses respectively, had evolved multiple known antibody escape mutations including
323 E484K, E484A, K417T, F490S, L452Q, and A475V⁴³⁻⁵⁰. Examining the consequences of these
324 mutations in the hamster infection model showed that the virus evolved from the Delta variant
325 had considerable antigenic distance from both ancestral SARS-CoV-2 and the Omicron
326 XBB.1.5 subvariant. Interestingly, hamster infection with XBB.1.5 failed to elicit neutralizing
327 immunity not only to the Delta variant evolved virus but also to ancestral SARS-CoV-2, in
328 agreement with recent results⁶⁴. The Delta variant evolved virus also showed extensive
329 escape from immunity elicited by Delta variant infections in people. However, it did not escape
330 more recent neutralizing immunity from vaccinated individuals with Omicron BA.1
331 breakthrough infection, nor from neutralizing immunity elicited by Omicron XBB subvariants.
332 It is likely that most of the BA.1 and XBB infected group have immunity from pre-Omicron
333 infections^{51,65}, and in the case of the XBB group, other Omicron subvariant infections⁶⁶.
334 Therefore, in contrast to the hamster experimental infections which used one virus, individuals
335 enrolled during the XBB period likely had hybrid immunity from multiple exposures, leading to
336 wider neutralization breadth⁵⁶ and accounting for the difference in the results.

337 In conclusion, we have found new evidence that neutralizing antibodies associate with SARS-
338 CoV-2 clearance and are likely required for such clearance to happen. However, the levels
339 need not be high. Furthermore, we have found that, while SARS-CoV-2 can evolve extensively
340 in long-term infection in advanced HIV disease, neutralizing antibody immunity from recent
341 infections, most likely combined with that acquired in past infections, may neutralize some of
342 the viruses evolved in this way. It is likely that such evolution during long-term infection in
343 immunosuppressed individuals occurs in other pathogens in HIV co-infections. Therefore,
344 investment in an effective global HIV treatment strategy may be necessary to reduce the
345 chances that this type of evolutionary process results in a pathogen with pandemic potential.

346

347 **Methods**

348 Informed consent and ethical statement

349 All blood samples used for neutralization studies, nasopharyngeal swabs from the advanced
350 HIV disease participants for outgrowth and sequencing, as well as nasopharyngeal swabs for
351 isolation of the ancestral/D614G, Beta, and Delta virus were obtained after written informed
352 consent from adults with PCR-confirmed SARS-CoV-2 infection enrolled in a prospective
353 cohort of SARS-CoV-2 infected individuals at the Africa Health Research Institute approved
354 by the Biomedical Research Ethics Committee at the University of KwaZulu–Natal (reference
355 BREC/00001275/2020). The Omicron/BA.1 virus was isolated from residual swab used for
356 diagnostic testing (Witwatersrand Human Research Ethics Committee reference M210752).
357 The nasopharyngeal swab for isolation of the Omicron XBB.1.5 subvariant was collected after
358 written informed consent as part of the COVID-19 transmission and natural history in KwaZulu-

359 Natal, South Africa: Epidemiological Investigation to Guide Prevention and Clinical Care in the
360 Centre for the AIDS Programme of Research in South Africa (CAPRISA) study and approved
361 by the Biomedical Research Ethics Committee at the University of KwaZulu–Natal (reference
362 BREC/00001195/2020, BREC/00003106/2021).

363 Reagent availability statement

364 Viral isolates are available upon reasonable request. Sequences of isolated SARS-CoV-2
365 used in this study have been deposited in GISAID with accession numbers as follows:

Virus	GISAID	Virus	GISAID
D614G	EPI_ISL_602626.1	0127-D10	EPI_ISL_16508746
Beta	EPI_ISL_678615	0127-D24	EPI_ISL_16508747
Delta	EPI_ISL_3118687	0127-D31	EPI_ISL_16508748
BA.1	EPI_ISL_7886688	0127-D38	EPI_ISL_16508749
0027-D6	EPI_ISL_15541746	0127-D54	EPI_ISL_18030392
0027-D20	EPI_ISL_15541747	0127-D68	EPI_ISL_16508751
0027-D34	EPI_ISL_15541748	0127-D192	EPI_ISL_14666773
0027-D71	EPI_ISL_15541749	0255-D209	EPI_ISL_14599778
0027-D106	EPI_ISL_15541750	0255-D211	EPI_ISL_14599779
0027-D190	EPI_ISL_2397313	0255-D219	EPI_ISL_14599780
0096-D1	EPI_ISL_14666761	0255-D237	EPI_ISL_13986497
0096-D15	EPI_ISL_14666763	0209-D5	EPI_ISL_18030393
0096-D32	EPI_ISL_13986492	0209-D26	EPI_ISL_18030394
0096-D68	EPI_ISL_18030390	0209-D144	EPI_ISL_12970433
0096-D77	EPI_ISL_18030391	0209-D159	EPI_ISL_14666777
0096-D110	EPI_ISL_14666766		

366

367 Clinical laboratory testing

368 SARS-CoV-2 Ct and HIV viral load quantification was performed from a nasopharyngeal swab
369 universal transport medium aliquot and 4 ml EDTA tube of blood respectively at an accredited
370 diagnostic laboratory (Molecular Diagnostic Services, Durban, South Africa). The CD4 count
371 was performed by an accredited diagnostic laboratory (Ampath, Durban, South Africa).

372 Detection of ART concentrations in plasma by LC-MS/MS

373 Sample analysis was performed using an Agilent High Pressure Liquid Chromatography
374 (HPLC) system coupled to the AB Sciex 5500, triple quadrupole mass spectrometer equipped
375 with an electrospray ionization (ESI) TurbolonSpray source. The LC-MS/MS method was
376 developed and optimized for the quantitation of tenofovir, lamivudine and dolutegravir in the
377 same sample. A protein precipitation extraction method using acetonitrile was used to process
378 50 µL plasma samples. 50 µL of water and 50 µL of ISTD solution was added and the sample
379 was briefly mixed. 150 µL of acetonitrile was subsequently added to facilitate protein
380 precipitation, vortex mixed and centrifuged at 16000 g for 10 min at 4°C. 170 µL of the clear
381 supernatant was then transferred to a clean micro-centrifuge tube and dried down using a
382 SpeedVac dryer set at 40°C. The dried samples were then reconstituted in 100 µL of 0.02%
383 sodium deoxycholate (Sigma) in Millipore filtered water, vortex mixed, briefly centrifuged,
384 placed in a small insert vial, capped, placed in the auto sampler compartment (maintained at
385 4°C) and analyzed using LC-MS/MS. The analytes were separated on an Agilent Zorbax
386 Eclipse Plus C18 HPLC column using gradient elution. The column oven was set at 40°C, a
387 sample volume of 2 µL was injected and the flow rate was set to 0.2 mL/min. Mobile phase A

388 consisted of water with 0.1% formic acid and B consisted of acetonitrile with 0.1% formic acid.
389 The drug analytes were monitored using multiple-reaction monitoring mode for positive ions
390 except for efavirenz which was monitored in the negative ion scan mode. Analyst software,
391 version 1.6.2 was used for quantitative data analysis. Blanked values for EFV, FTC and TFV
392 were in the range of 3 ng/mL and this was set as the detection limit.

393 Whole-genome sequencing

394 RNA was extracted on an automated Chemagic 360 instrument, using the CMG-1049 kit
395 (Perkin Elmer, Hamburg, Germany). The RNA was stored at -80°C prior to use. Libraries for
396 whole genome sequencing were prepared using either the Oxford Nanopore Midnight protocol
397 with Rapid Barcoding or the Illumina COVIDseq Assay. For the Illumina COVIDseq assay, the
398 libraries were prepared according to the manufacturer's protocol. Briefly, amplicons were
399 tagmented, followed by indexing using the Nextera UD Indexes Set A. Sequencing libraries
400 were pooled, normalized to 4 nM and denatured with 0.2 N sodium acetate. An 8 pM sample
401 library was spiked with 1% PhiX (PhiX Control v3 adaptor-ligated library used as a control).
402 We sequenced libraries on a 500-cycle v2 MiSeq Reagent Kit on the Illumina MiSeq
403 instrument (Illumina). On the Illumina NextSeq 550 instrument, sequencing was performed
404 using the Illumina COVIDSeq protocol (Illumina Inc, USA), an amplicon-based next-generation
405 sequencing approach. The first strand synthesis was carried using random hexamers primers
406 from Illumina and the synthesized cDNA underwent two separate multiplex PCR reactions.
407 The pooled PCR amplified products were processed for tagmentation and adapter ligation
408 using IDT for Illumina Nextera UD Indexes. Further enrichment and cleanup was performed
409 as per protocols provided by the manufacturer (Illumina Inc). Pooled samples were quantified
410 using Qubit 3.0 or 4.0 fluorometer (Invitrogen Inc.) using the Qubit dsDNA High Sensitivity
411 assay according to manufacturer's instructions. The fragment sizes were analyzed using
412 TapeStation 4200 (Invitrogen). The pooled libraries were further normalized to 4nM
413 concentration and 25 μL of each normalized pool containing unique index adapter sets were
414 combined in a new tube. The final library pool was denatured and neutralized with 0.2N sodium
415 hydroxide and 200 mM Tris-HCL (pH7), respectively. 1.5 pM sample library was spiked with
416 2% PhiX. Libraries were loaded onto a 300-cycle NextSeq 500/550 HighOutput Kit v2 and run
417 on the Illumina NextSeq 550 instrument (Illumina, San Diego, CA, USA). For Oxford Nanopore
418 sequencing, the Midnight primer kit was used as described by Freed and Silander55. cDNA
419 synthesis was performed on the extracted RNA using LunaScript RT mastermix (New England
420 BioLabs) followed by gene-specific multiplex PCR using the Midnight Primer pools which
421 produce 1200bp amplicons which overlap to cover the 30-kb SARS-CoV-2 genome.
422 Amplicons from each pool were pooled and used neat for barcoding with the Oxford Nanopore
423 Rapid Barcoding kit as per the manufacturer's protocol. Barcoded samples were pooled and
424 bead-purified. After the bead clean-up, the library was loaded on a prepared R9.4.1 flow-cell.
425 A GridION X5 or MinION sequencing run was initiated using MinKNOW software with the
426 base-call setting switched off. We assembled paired-end and nanopore.fastq reads using
427 Genome Detective 1.132 (<https://www.genomedetective.com>) which was updated for the
428 accurate assembly and variant calling of tiled primer amplicon Illumina or Oxford Nanopore
429 reads, and the Coronavirus Typing Tool. For Illumina assembly, GATK HaploTypeCaller --
430 min-pruning 0 argument was added to increase mutation calling sensitivity near sequencing
431 gaps. For Nanopore, low coverage regions with poor alignment quality (<85% variant
432 homogeneity) near sequencing/amplicon ends were masked to be robust against primer drop-
433 out experienced in the Spike gene, and the sensitivity for detecting short inserts using a region-
434 local global alignment of reads, was increased. In addition, we also used the wf_artic (ARTIC
435 SARS-CoV-2) pipeline as built using the nextflow workflow framework. In some instances,
436 mutations were confirmed visually with .bam files using Geneious software V2020.1.2

437 (Biomatters). The reference genome used throughout the assembly process was
438 NC_045512.2 (numbering equivalent to MN908947.3). To determine which SARS-CoV-2
439 proteins were mutated, sequence was input into the sequence analysis application in the
440 Stanford Coronavirus Antiviral and Resistance Database
441 (<https://covdb.stanford.edu/sierra/sars2/by-sequences/>) with HTML as output. Mutations were
442 then visualized in Excel relative to the infecting variant.

443 Phylogenetic analysis

444 Sequences were aligned by Nextclade version 2.9.1 (<https://clades.nextstrain.org/>). The json
445 file output from the Nextclade analysis was loaded into Auspice (<https://auspice.us/>).
446 Visualization was filtered to include reference sequences from clades 20A, 20B, 20H (Beta),
447 21J (Delta), 21M, 21K, 21L and 22B (Omicron), and the input sequences (new nodes), for a
448 combined 1408 genomes. The tree was then filtered to show new nodes only. Tip labels were
449 removed and SVG downloaded for final processing using Microsoft Powerpoint software.

450 Cells

451 The H1299-E3 (H1299-ACE2, clone E3) cell line used in the live virus infections was derived
452 from H1299 (CRL-5803) as described in previous work^{55,67} and propagated in growth medium
453 consisting of complete Roswell Park Memorial Institute (RPMI) 1640 with 10% fetal bovine
454 serum containing 10mM of HEPES, 1mM sodium pyruvate, 2mM L-glutamine and 0.1mM
455 nonessential amino acids.

456 Live virus neutralization assay

457 H1299-E3 cells were plated in a 96-well plate (Corning) at 30,000 cells per well 1 day pre-
458 infection. Plasma was separated from EDTA-anticoagulated blood by centrifugation at 500 rcf
459 for 10 min and stored at -80 °C. Aliquots of plasma samples were heat-inactivated at 56 °C
460 for 30 min and clarified by centrifugation at 10,000 rcf for 5 min. Virus stocks were used at
461 approximately 50-100 focus-forming units per microwell and added to diluted plasma.
462 Antibody-virus mixtures were incubated for 1 h at 37 °C, 5% CO₂. Cells were infected with
463 100 µL of the virus-antibody mixtures for 1 h, then 100 µL of a 1X RPMI 1640 (Sigma-Aldrich,
464 R6504), 1.5% carboxymethylcellulose (Sigma-Aldrich, C4888) overlay was added without
465 removing the inoculum. Cells were fixed 18 h post-infection using 4% PFA (Sigma-Aldrich) for
466 20 min. Foci were stained with a rabbit anti-spike monoclonal antibody (BS-R2B12, GenScript
467 A02058) at 0.5 µg/mL in a permeabilization buffer containing 0.1% saponin (Sigma-Aldrich),
468 0.1% BSA (Sigma-Aldrich) and 0.05% Tween-20 (Sigma-Aldrich) in PBS. Plates were
469 incubated with primary antibody overnight at 4 °C, then washed with wash buffer containing
470 0.05% Tween-20 in PBS. Secondary goat anti-rabbit HRP conjugated antibody (Abcam
471 ab205718) was added at 1 µg/mL and incubated for 2 h at room temperature with shaking.
472 TrueBlue peroxidase substrate (SeraCare 5510-0030) was then added at 50 µL per well and
473 incubated for 20 min at room temperature. Plates were imaged in an ImmunoSpot Ultra-V S6-
474 02-6140 Analyzer ELISPOT instrument with BioSpot Professional built-in image analysis
475 (C.T.L).

476 Statistics and fitting

477 All statistics and fitting were performed using custom code in MATLAB v.2019b. Neutralization
478 data were fit to:

$$479 \quad T_x = 1 / (1 + (D / ID_{50})) \quad (1)$$

480 Here T_x is the number of foci at plasma dilution D normalized to the number of foci in the
481 absence of plasma on the same plate. ID_{50} is the plasma dilution giving 50% neutralization.

482 $FRNT_{50} = 1/ID_{50}$. Values of $FRNT_{50} < 1$ are set to 1 (undiluted), the lowest measurable value.
483 We note that the most concentrated plasma dilution was 1:25 and therefore $FRNT_{50} < 25$ were
484 extrapolated.
485

486 SARS-CoV-2 spike enzyme-linked immunosorbent assay (ELISA)

487 Two µg/mL of spike protein was used to coat 96-well, high-binding plates and incubated
488 overnight at 4°C. The plates were incubated in a blocking buffer consisting of 5% skimmed
489 milk powder, 0.05% Tween 20, 1x PBS. Plasma samples were diluted to 1:100 starting dilution
490 in a blocking buffer and added to the plates. Secondary antibody was diluted to 1:3000 or
491 1:1000 respectively in blocking buffer and added to the plates followed by TMB substrate
492 (ThermoFisher Scientific). Upon stopping the reaction with 1 M H₂SO₄, absorbance was
493 measured at a 450nm wavelength. MAbs CR3022 and BD23 were used as positive controls
494 and Palivizumab was used as a negative control.

495 SARS-CoV-2 hamster infections

496 Golden Syrian hamsters (4-5 weeks old) were purchased from Charles River Laboratories,
497 USA. Experimental work was approved by the Animal Ethics Committee at the University of
498 KwaZulu Natal (reference: REC/00004197/2022). For SARS-CoV-2 infection, hamsters were
499 lightly sedated with 3% isoflurane (Piramal Healthcare, Mumbai, India) and infected with virus
500 by intranasal inoculation of 50 µL per nostril of virus solution. Plasma of infected animals and
501 uninfected controls was collected at 16 days post infection using cardiac puncture under
502 anaesthesia with 5% isoflurane. Hamsters were immediately euthanized post-puncture with 1
503 mL of 200 mg/mL sodium pentobarbitone solution (Bayer AG, Leverkusen, Germany). Plasma
504 was separated by centrifugation at 1000 x g for 10 min. Aliquots of plasma samples were heat-
505 inactivated at 56 °C for 30 min and clarified by centrifugation at 10,000 rcf for 5 min.

506 Acknowledgements

507 This study was supported by the Bill and Melinda Gates award INV-018944 (AS), Wellcome
508 Trust Award 226137/Z/22/Z (AS and PLM) and the South African Medical Research Council
509 (AS and PLM). PLM is supported by the South African Research Chairs Initiative of the
510 Department of Science and Innovation and National Research Foundation of South Africa.
511 The funders had no role in study design, data collection and analysis, decision to publish, or
512 preparation of the manuscript. AS wishes to thank Ron Milo, Karen Makar, and Thandi Onami
513 for discussion and suggestions on analysis and presentation of results.

514 Competing interest statement

515 The authors declare no competing interests.

516 Author contributions

517 AS and FK conceived the study and designed the study and experiments. FK, KK, MB, JU,
518 GL, QAK, SSKA, and AvG identified and provided virus samples. M-YSM, FK, BIG, MB, KK,
519 NM, NMa, MM, and NN set up and managed the cohort and cohort data. KK, ZJ, KR, YG, EV,
520 ZM, and KG performed experiments and sequence analysis with input from AS, TdO, RJL.
521 AS, FK, MB, JU, RJL, and GL interpreted data with input from M-YSM, SSKA, WH, and TdO.
522 AS, FK, and GL prepared the manuscript with input from all authors.

523

524

525

526 References

- 527 1 Plotkin, S. A. Correlates of Protection Induced by Vaccination. *Clinical and Vaccine*
528 *Immunology* **17**, 1055-1065 (2010). doi:10.1128/CVI.00131-10
- 529
- 530 2 Khoury, D. S., Cromer, D., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Subbarao, K.,
531 Kent, S. J., Triccas, J. A. & Davenport, M. P. Neutralizing antibody levels are highly predictive
532 of immune protection from symptomatic SARS-CoV-2 infection. *Nature medicine*, 1-7 (2021).
- 533 3 Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Sasson, S. C., Kent, S. J., Khoury, D. S. &
534 Davenport, M. P. Neutralising antibodies predict protection from severe COVID-19. *medRxiv*,
535 2022.2006.2009.22275942 (2022). 10.1101/2022.06.09.22275942
- 536
- 537 4 Cele, S., Karim, F., Lustig, G., San, J. E., Hermanus, T., Tegally, H., Snyman, J., Moyo-Gwete, T.,
538 Wilkinson, E., Bernstein, M., Khan, K., Hwa, S.-H., Tilles, S. W., Singh, L., Giandhari, J.,
539 Mthabela, N., Mazibuko, M., Ganga, Y., Gosnell, B. I., Abdool Karim, S. S., Hanekom, W., Van
540 Voorhis, W. C., Ndung'u, T., Lessells, R. J., Moore, P. L., Moosa, M.-Y. S., de Oliveira, T. &
541 Sigal, A. SARS-CoV-2 prolonged infection during advanced HIV disease evolves extensive
542 immune escape. *Cell Host & Microbe* (2022). 10.1016/j.chom.2022.01.005
- 543
- 544 5 Karim, F., Moosa, M. Y., Gosnell, B., Sandile, C., Giandhari, J., Pillay, S., Tegally, H., Wilkinson,
545 E., San, E. J. & Msomi, N. Persistent SARS-CoV-2 infection and intra-host evolution in
546 association with advanced HIV infection. *medRxiv* (2021).
- 547 6 Riddell, A. C., Kele, B., Harris, K., Bible, J., Murphy, M., Dakshina, S., Storey, N., Owoyemi, D.,
548 Pade, C., Gibbons, J. M., Harrington, D., Alexander, E., McKnight, Á. & Cutino-Moguel, T.
549 Generation of novel SARS-CoV-2 variants on B.1.1.7 lineage in three patients with advanced
550 HIV disease. *Clin Infect Dis* (2022). PMC9213850. 10.1093/cid/ciac409
- 551
- 552 7 Kemp, S. A., Collier, D. A., Datir, R. P., Ferreira, I., Gayed, S., Jahun, A., Hosmillo, M., Rees-
553 Spear, C., Mlcochova, P., Lumb, I. U., Roberts, D. J., Chandra, A., Temperton, N.,
554 Collaboration, C.-N. B. C.-., Consortium, C.-G. U., Sharrocks, K., Blane, E., Modis, Y., Leigh, K.
555 E., Briggs, J. A. G., van Gils, M. J., Smith, K. G. C., Bradley, J. R., Smith, C., Doffinger, R., Ceron-
556 Gutierrez, L., Barcenas-Morales, G., Pollock, D. D., Goldstein, R. A., Smielewska, A., Skittrall,
557 J. P., Gouliouris, T., Goodfellow, I. G., Gkrania-Klotsas, E., Illingworth, C. J. R., McCoy, L. E. &
558 Gupta, R. K. SARS-CoV-2 evolution during treatment of chronic infection. *Nature* **592**, 277-
559 282 (2021). PMC7610568. 10.1038/s41586-021-03291-y
- 560
- 561 8 Peacock, T. P., Penrice-Randal, R., Hiscox, J. A. & Barclay, W. S. SARS-CoV-2 one year on:
562 evidence for ongoing viral adaptation. *The Journal of General Virology* **102** (2021).
- 563 9 Jensen, B., Luebke, N., Feldt, T., Keitel, V., Brandenburger, T., Kindgen-Milles, D., Lutterbeck,
564 M., Freise, N., Schoeler, D. & Haas, R. Emergence of the E484K mutation in SARS-COV-2-
565 infected immunocompromised patients treated with bamlanivimab in Germany. *Lancet Reg*
566 *Health Eur.* 2021; 8: 100164. *J. LANEPE* (2021).
- 567 10 Baang, J. H., Smith, C., Mirabelli, C., Valesano, A. L., Manthei, D. M., Bachman, M. A., Wobus,
568 C. E., Adams, M., Washer, L., Martin, E. T. & Luring, A. S. Prolonged Severe Acute
569 Respiratory Syndrome Coronavirus 2 Replication in an Immunocompromised Patient. *J Infect*
570 *Dis* **223**, 23-27 (2021). PMC7797758. 10.1093/infdis/jiaa666

571

- 572 11 Choi, B., Choudhary, M. C., Regan, J., Sparks, J. A., Padera, R. F., Qiu, X., Solomon, I. H., Kuo,
573 H. H., Boucau, J., Bowman, K., Adhikari, U. D., Winkler, M. L., Mueller, A. A., Hsu, T. Y.,
574 Desjardins, M., Baden, L. R., Chan, B. T., Walker, B. D., Lichterfeld, M., Brigl, M., Kwon, D. S.,
575 Kanjilal, S., Richardson, E. T., Jonsson, A. H., Alter, G., Barczak, A. K., Hanage, W. P., Yu, X. G.,
576 Gaiha, G. D., Seaman, M. S., Cernadas, M. & Li, J. Z. Persistence and Evolution of SARS-CoV-2
577 in an Immunocompromised Host. *N Engl J Med* **383**, 2291-2293 (2020). PMC7673303.
578 10.1056/NEJMc2031364
- 579
- 580 12 Avanzato, V. A., Matson, M. J., Seifert, S. N., Pryce, R., Williamson, B. N., Anzick, S. L.,
581 Barbian, K., Judson, S. D., Fischer, E. R., Martens, C., Bowden, T. A., de Wit, E., Riedo, F. X. &
582 Munster, V. J. Case Study: Prolonged Infectious SARS-CoV-2 Shedding from an Asymptomatic
583 Immunocompromised Individual with Cancer. *Cell* **183**, 1901-1912.e1909 (2020).
584 PMC7640888. 10.1016/j.cell.2020.10.049
- 585
- 586 13 Wilkinson, S. A. J., Richter, A., Casey, A., Osman, H., Mirza, J. D., Stockton, J., Quick, J.,
587 Ratcliffe, L., Sparks, N., Cumley, N., Poplawski, R., Nicholls, S. N., Kele, B., Harris, K., Peacock,
588 T. P. & Loman, N. J. Recurrent SARS-CoV-2 mutations in immunodeficient patients. *Virus Evol*
589 **8**, veac050 (2022). PMC9384748. 10.1093/ve/veac050
- 590
- 591 14 Maponga, T. G., Jeffries, M., Tegally, H., Sutherland, A., Wilkinson, E., Lessells, R. J., Msomi,
592 N., van Zyl, G., de Oliveira, T. & Preiser, W. Persistent SARS-CoV-2 infection with
593 accumulation of mutations in a patient with poorly controlled HIV infection. *Clin Infect Dis*
594 (2022). PMC9278209. 10.1093/cid/ciac548
- 595
- 596 15 Hoffman, S. A., Costales, C., Sahoo, M. K., Palanisamy, S., Yamamoto, F., Huang, C., Verghese,
597 M., Solis, D. C., Sibai, M. & Subramanian, A. SARS-CoV-2 Neutralization Resistance Mutations
598 in Patient with HIV/AIDS, California, USA. *Emerging Infectious Diseases* **27** (2021).
599 16 Corey, L., Beyrer, C., Cohen, M. S., Michael, N. L., Bedford, T. & Rolland, M. SARS-CoV-2
600 Variants in Patients with Immunosuppression. *N Engl J Med* **385**, 562-566 (2021).
601 PMC8494465. 10.1056/NEJMs2104756
- 602
- 603 17 Tanner, J. R. & Kingsley, R. A. Evolution of Salmonella within Hosts. *Trends Microbiol* **26**, 986-
604 998 (2018). PMC6249985. 10.1016/j.tim.2018.06.001
- 605
- 606 18 Xue, K. S., Moncla, L. H., Bedford, T. & Bloom, J. D. Within-Host Evolution of Human
607 Influenza Virus. *Trends Microbiol* **26**, 781-793 (2018). PMC6097882.
608 10.1016/j.tim.2018.02.007
- 609
- 610 19 Kistler, K. E., Huddleston, J. & Bedford, T. Rapid and parallel adaptive mutations in spike S1
611 drive clade success in SARS-CoV-2. *Cell Host Microbe* **30**, 545-555.e544 (2022). PMC8938189.
612 10.1016/j.chom.2022.03.018
- 613
- 614 20 Lustig, G., Ganga, Y., Rodel, H., Tegally, H., Jackson, L., Cele, S., Khan, K., Jule, Z., Reedoy, K.,
615 Karim, F., Bernstein, M., Moosa, M.-Y. S., Archary, D., de Oliveira, T., Lessells, R., Abdool
616 Karim, S. S. & Sigal, A. SARS-CoV-2 evolves increased infection elicited cell death and fusion
617 in an immunosuppressed individual. *medRxiv*, 2022.2011.2023.22282673 (2022).
618 10.1101/2022.11.23.22282673

- 619
620 21 Banda, N. K., Bernier, J., Kurahara, D. K., Kurrle, R., Haigwood, N., Sekaly, R. P. & Finkel, T. H.
621 Crosslinking CD4 by human immunodeficiency virus gp120 primes T cells for activation-
622 induced apoptosis. *J Exp Med* **176**, 1099-1106 (1992). PMC2119378.
623 10.1084/jem.176.4.1099
- 624
625 22 Westendorp, M. O., Frank, R., Ochsenbauer, C., Stricker, K., Dhein, J., Walczak, H., Debatin,
626 K. M. & Krammer, P. H. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and
627 gp120. *Nature* **375**, 497-500 (1995). 10.1038/375497a0
- 628
629 23 Westendorp, M. O., Shatrov, V. A., Schulze-Osthoff, K., Frank, R., Kraft, M., Los, M.,
630 Krammer, P. H., Dröge, W. & Lehmann, V. HIV-1 Tat potentiates TNF-induced NF-kappa B
631 activation and cytotoxicity by altering the cellular redox state. *Embo j* **14**, 546-554 (1995).
632 PMC398112. 10.1002/j.1460-2075.1995.tb07030.x
- 633
634 24 Cooper, A., García, M., Petrovas, C., Yamamoto, T., Koup, R. A. & Nabel, G. J. HIV-1 causes
635 CD4 cell death through DNA-dependent protein kinase during viral integration. *Nature* **498**,
636 376-379 (2013). 10.1038/nature12274
- 637
638 25 Zeng, M., Haase, A. T. & Schacker, T. W. Lymphoid tissue structure and HIV-1 infection: life
639 or death for T cells. *Trends Immunol* **33**, 306-314 (2012). 10.1016/j.it.2012.04.002
- 640
641 26 Monroe, K. M., Yang, Z., Johnson, J. R., Geng, X., Doitsh, G., Krogan, N. J. & Greene, W. C.
642 IFI16 DNA sensor is required for death of lymphoid CD4 T cells abortively infected with HIV.
643 *Science* **343**, 428-432 (2014). PMC3976200. 10.1126/science.1243640
- 644
645 27 Doitsh, G., Cavrois, M., Lassen, K. G., Zepeda, O., Yang, Z., Santiago, M. L., Hebbeler, A. M. &
646 Greene, W. C. Abortive HIV infection mediates CD4 T cell depletion and inflammation in
647 human lymphoid tissue. *Cell* **143**, 789-801 (2010). PMC3026834. 10.1016/j.cell.2010.11.001
- 648
649 28 Doitsh, G., Galloway, N. L., Geng, X., Yang, Z., Monroe, K. M., Zepeda, O., Hunt, P. W.,
650 Hatano, H., Sowinski, S., Muñoz-Arias, I. & Greene, W. C. Cell death by pyroptosis drives CD4
651 T-cell depletion in HIV-1 infection. *Nature* **505**, 509-514 (2014). PMC4047036.
652 10.1038/nature12940
- 653
654 29 Galloway, N. L., Doitsh, G., Monroe, K. M., Yang, Z., Muñoz-Arias, I., Levy, D. N. & Greene, W.
655 C. Cell-to-Cell Transmission of HIV-1 Is Required to Trigger Pyroptotic Death of Lymphoid-
656 Tissue-Derived CD4 T Cells. *Cell Rep* **12**, 1555-1563 (2015). PMC4565731.
657 10.1016/j.celrep.2015.08.011
- 658
659 30 Sepkowitz, K. A., Raffalli, J., Riley, L., Kiehn, T. E. & Armstrong, D. Tuberculosis in the AIDS
660 era. *Clinical Microbiology Reviews* **8**, 180-199 (1995).
- 661 31 Bell, L. C. & Noursadeghi, M. Pathogenesis of HIV-1 and Mycobacterium tuberculosis co-
662 infection. *Nature Reviews Microbiology* **16**, 80-90 (2018).
- 663 32 Chen, L., Zody, M. C., Di Germanio, C., Martinelli, R., Mediavilla, J. R., Cunningham, M. H.,
664 Composto, K., Chow, K. F., Kordalewska, M., Corvelo, A., Oschwald, D. M., Fennessey, S.,

- 665 Zetkusic, M., Dar, S., Kramer, Y., Mathema, B., Germer, S., Stone, M., Simmons, G., Busch, M.
666 P., Maniatis, T., Perlin, D. S. & Kreiswirth, B. N. Emergence of Multiple SARS-CoV-2 Antibody
667 Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma
668 Treatment. *mSphere* **6**, e0048021 (2021). PMC8386433. 10.1128/mSphere.00480-21
- 669
670 33 Karatas, A., Inkaya, A. C., Demiroglu, H., Aksu, S., Haziyeve, T., Cinar, O. E., Alp, A., Uzun, O.,
671 Sayinalp, N. & Goker, H. Prolonged viral shedding in a lymphoma patient with COVID-19
672 infection receiving convalescent plasma. *Transfus Apher Sci* **59**, 102871 (2020).
673 PMC7333597. 10.1016/j.transci.2020.102871
- 674
675 34 Li, Y., Choudhary, M. C., Regan, J., Boucau, J., Nathan, A., Speidel, T., Liew, M. Y., Edelstein,
676 G. E., Kawano, Y., Uddin, R., Deo, R., Marino, C., Getz, M. A., Reynold, Z., Barry, M., Gilbert,
677 R. F., Tien, D., Sagar, S., Vyas, T. D., Flynn, J. P., Hammond, S. P., Novack, L. A., Choi, B.,
678 Cernadas, M., Wallace, Z. S., Sparks, J. A., Vyas, J. M., Seaman, M. S., Gaiha, G. D., Siedner,
679 M. J., Barczak, A. K., Lemieux, J. E. & Li, J. Z. SARS-CoV-2 Viral Clearance and Evolution Varies
680 by Extent of Immunodeficiency. *medRxiv*, 2023.2007.2031.23293441 (2023).
681 10.1101/2023.07.31.23293441
- 682
683 35 UNAIDS. *HIV and AIDS Estimates South Africa 2021*, (2021).
- 684
685 36 Carmona, S., Bor, J., Nattey, C., Maughan-Brown, B., Maskew, M., Fox, M. P., Glencross, D.
686 K., Ford, N. & MacLeod, W. B. Persistent High Burden of Advanced HIV Disease Among
687 Patients Seeking Care in South Africa's National HIV Program: Data From a Nationwide
688 Laboratory Cohort. *Clinical Infectious Diseases* **66**, S111-S117 (2018). 10.1093/cid/ciy045
- 689
690 37 Chihana, M. L., Huerga, H., Van Cutsem, G., Ellman, T., Goemaere, E., Wanjala, S., Masiku, C.,
691 Szumilin, E., Etard, J. F., Maman, D. & Davies, M. A. Distribution of advanced HIV disease
692 from three high HIV prevalence settings in Sub-Saharan Africa: a secondary analysis data
693 from three population-based cross-sectional surveys in Eshowe (South Africa), Ndhiwa
694 (Kenya) and Chiradzulu (Malawi). *Glob Health Action* **12**, 1679472 (2019). PMC6844432.
695 10.1080/16549716.2019.1679472
- 696
697 38 Antinori, A., Cicalini, S., Meschi, S., Bordoni, V., Lorenzini, P., Vergori, A., Lanini, S., De
698 Pascale, L., Matusali, G., Mariotti, D., Cozzi Lepri, A., Gallì, P., Pinnetti, C., Gagliardini, R.,
699 Mazzotta, V., Mastroianni, I., Grisetti, S., Colavita, F., Cimini, E., Grilli, E., Bellagamba, R.,
700 Lapa, D., Sacchi, A., Marani, A., Cerini, C., Candela, C., Fusto, M., Puro, V., Castilletti, C.,
701 Agrati, C., Girardi, E., Vaia, F. & Group, f. t. H.-V. S. Humoral and Cellular Immune Response
702 Elicited by mRNA Vaccination Against Severe Acute Respiratory Syndrome Coronavirus 2
703 (SARS-CoV-2) in People Living With Human Immunodeficiency Virus Receiving Antiretroviral
704 Therapy Based on Current CD4 T-Lymphocyte Count. *Clinical Infectious Diseases* **75**, e552-
705 e563 (2022). 10.1093/cid/ciac238
- 706
707 39 Spinelli, M. A., Lynch, K. L., Yun, C., Glidden, D. V., Peluso, M. J., Henrich, T. J., Gandhi, M. &
708 Brown, L. B. SARS-CoV-2 seroprevalence, and IgG concentration and pseudovirus
709 neutralising antibody titres after infection, compared by HIV status: a matched case-control
710 observational study. *Lancet HIV* (2021). PMC8084354 National Institutes of Health during

- 711 conduct of the study. DVG reports personal fees from Gilead Sciences outside the submitted
712 work. All other authors declare no competing interests. 10.1016/S2352-3018(21)00072-2
- 713
- 714 40 Vergori, A., Cozzi Lepri, A., Cicalini, S., Matusali, G., Bordoni, V., Lanini, S., Meschi, S.,
715 Iannazzo, R., Mazzotta, V., Colavita, F., Mastroiosa, I., Cimini, E., Mariotti, D., De Pascale, L.,
716 Marani, A., Galli, P., Garbuglia, A., Castilletti, C., Puro, V., Agrati, C., Girardi, E., Vaia, F.,
717 Antinori, A., Amendola, A., Baldini, F., Bellagamba, R., Bettini, A., Bordi, L., Camici, M.,
718 Casetti, R., Costantini, S., Cristofanelli, F., D'Alessio, C., D'Aquila, V., De Angelis, A., De Zottis,
719 F., de Pascale, L., Francalancia, M., Fusto, M., Gagliardini, R., Gramigna, G., Grassi, G., Grilli,
720 E., Grisetti, S., Iafra, D., Lapa, D., Lorenzini, P., Marani, A., Masone, E., Marongiu, S., Mondì,
721 A., Notari, S., Ottou, S., Paulicelli, J., Pellegrino, L., Pinnetti, C., Plazzi, M. M., Poggi, A., Sacchi,
722 A., Tartaglia, E. & group, H.-V. s. Immunogenicity to COVID-19 mRNA vaccine third dose in
723 people living with HIV. *Nature Communications* **13**, 4922 (2022). 10.1038/s41467-022-
724 32263-7
- 725
- 726 41 Vanaskova, E., Kelbich, P. & Novotny, T. Reactive synovitis of the knee joint after COVID-19
727 vaccination: The first ultrastructural analysis of synovial fluid. *Int J Rheum Dis* **25**, 1324-1327
728 (2022). PMC9538559. 10.1111/1756-185x.14411
- 729
- 730 42 Parperis, K. & Constantinou, M. Remitting seronegative symmetrical synovitis with pitting
731 oedema following BNT162b2 mRNA COVID-19 vaccination. *BMJ Case Reports* **14**, e244479
732 (2021). 10.1136/bcr-2021-244479
- 733
- 734 43 Greaney, A. J., Loes, A. N., Crawford, K. H. D., Starr, T. N., Malone, K. D., Chu, H. Y. & Bloom,
735 J. D. Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that
736 affect recognition by polyclonal human plasma antibodies. *Cell Host Microbe* **29**, 463-
737 476.e466 (2021). PMC7869748. 10.1016/j.chom.2021.02.003
- 738
- 739 44 Greaney, A. J., Starr, T. N., Barnes, C. O., Weisblum, Y., Schmidt, F., Caskey, M., Gaebler, C.,
740 Cho, A., Agudelo, M., Finkin, S., Wang, Z., Poston, D., Muecksch, F., Hatziioannou, T.,
741 Bieniasz, P. D., Robbani, D. F., Nussenzweig, M. C., Bjorkman, P. J. & Bloom, J. D. Mapping
742 mutations to the SARS-CoV-2 RBD that escape binding by different classes of antibodies.
743 *Nature Communications* **12**, 4196 (2021). 10.1038/s41467-021-24435-8
- 744
- 745 45 Barnes, C. O., Jette, C. A., Abernathy, M. E., Dam, K. A., Esswein, S. R., Gristick, H. B.,
746 Malyutin, A. G., Sharaf, N. G., Huey-Tubman, K. E., Lee, Y. E., Robbani, D. F., Nussenzweig,
747 M. C., West, A. P., Jr. & Bjorkman, P. J. SARS-CoV-2 neutralizing antibody structures inform
748 therapeutic strategies. *Nature* **588**, 682-687 (2020). PMC8092461. 10.1038/s41586-020-
749 2852-1
- 750
- 751 46 Wang, M., Zhang, L., Li, Q., Wang, B., Liang, Z., Sun, Y., Nie, J., Wu, J., Su, X., Qu, X., Li, Y.,
752 Wang, Y. & Huang, W. Reduced sensitivity of the SARS-CoV-2 Lambda variant to monoclonal
753 antibodies and neutralizing antibodies induced by infection and vaccination. *Emerging*
754 *Microbes & Infections* **11**, 18-29 (2022). 10.1080/22221751.2021.2008775
- 755
- 756 47 Muecksch, F., Weisblum, Y., Barnes, C. O., Schmidt, F., Schaefer-Babajew, D., Wang, Z., JC, C.
757 L., Flyak, A. I., DeLaitch, A. T., Huey-Tubman, K. E., Hou, S., Schiffer, C. A., Gaebler, C., Da

- 758 Silva, J., Poston, D., Finkin, S., Cho, A., Cipolla, M., Oliveira, T. Y., Millard, K. G., Ramos, V.,
759 Gazumyan, A., Rutkowska, M., Caskey, M., Nussenzweig, M. C., Bjorkman, P. J.,
760 Hatzioannou, T. & Bieniasz, P. D. Affinity maturation of SARS-CoV-2 neutralizing antibodies
761 confers potency, breadth, and resilience to viral escape mutations. *Immunity* **54**, 1853-
762 1868.e1857 (2021). PMC8323339. 10.1016/j.immuni.2021.07.008
- 763
- 764 48 Wang, Q., Guo, Y., Iketani, S., Nair, M. S., Li, Z., Mohri, H., Wang, M., Yu, J., Bowen, A. D.,
765 Chang, J. Y., Shah, J. G., Nguyen, N., Chen, Z., Meyers, K., Yin, M. T., Sobieszczyk, M. E.,
766 Sheng, Z., Huang, Y., Liu, L. & Ho, D. D. Antibody evasion by SARS-CoV-2 Omicron subvariants
767 BA.2.12.1, BA.4 and BA.5. *Nature* **608**, 603-608 (2022). 10.1038/s41586-022-05053-w
- 768
- 769 49 Starr, T. N., Greaney, A. J., Addetia, A., Hannon, W. W., Choudhary, M. C., Dings, A. S., Li, J.
770 Z. & Bloom, J. D. Prospective mapping of viral mutations that escape antibodies used to treat
771 COVID-19. *Science* **371**, 850-854 (2021). PMC7963219. 10.1126/science.abf9302
- 772
- 773 50 Tada, T., Zhou, H., Dcosta, B. M., Samanovic, M. I., Chivukula, V., Herati, R. S., Hubbard, S. R.,
774 Mulligan, M. J. & Landau, N. R. Increased resistance of SARS-CoV-2 Omicron variant to
775 neutralization by vaccine-elicited and therapeutic antibodies. *EBioMedicine* **78**, 103944
776 (2022). PMC9021600. 10.1016/j.ebiom.2022.103944
- 777
- 778 51 Madhi, S. A., Kwatra, G., Myers, J. E., Jassat, W., Dhar, N., Mukendi, C. K., Nana, A. J.,
779 Blumberg, L., Welch, R., Ngorima-Mabhena, N. & Mutevedzi, P. C. Population Immunity and
780 Covid-19 Severity with Omicron Variant in South Africa. *New England Journal of Medicine*
781 (2022). 10.1056/NEJMoa2119658
- 782
- 783 52 Mykytyn, A. Z., Rosu, M. E., Kok, A., Rissmann, M., van Amerongen, G., Geurtsvankessel, C.,
784 de Vries, R. D., Munnink, B. B. O., Smith, D. J., Koopmans, M. P. G., Lamers, M. M., Fouchier,
785 R. A. M. & Haagmans, B. L. Antigenic mapping of emerging SARS-CoV-2 omicron variants
786 BM.1.1.1, BQ.1.1, and XBB.1. *Lancet Microbe* **4**, e294-e295 (2023). PMC9842387.
787 10.1016/s2666-5247(22)00384-6
- 788
- 789 53 Smith, D. J., Lapedes, A. S., De Jong, J. C., Bestebroer, T. M., Rimmelzwaan, G. F., Osterhaus,
790 A. D. & Fouchier, R. A. Mapping the antigenic and genetic evolution of influenza virus.
791 *science* **305**, 371-376 (2004).
- 792 54 Rössler, A., Netzl, A., Knabl, L., Schäfer, H., Wilks, S. H., Bante, D., Falkensammer, B., Borena,
793 W., von Laer, D., Smith, D. J. & Kimpel, J. BA.2 and BA.5 omicron differ immunologically from
794 both BA.1 omicron and pre-omicron variants. *Nat Commun* **13**, 7701 (2022). PMC9745279.
795 10.1038/s41467-022-35312-3
- 796
- 797 55 Cele, S., Jackson, L., Khoury, D. S., Khan, K., Moyo-Gwete, T., Tegally, H., San, J. E., Cromer,
798 D., Scheepers, C., Amoako, D. G., Karim, F., Bernstein, M., Lustig, G., Archary, D., Smith, M.,
799 Ganga, Y., Jule, Z., Reedoy, K., Hwa, S. H., Giandhari, J., Blackburn, J. M., Gosnell, B. I., Abdool
800 Karim, S. S., Hanekom, W., von Gottberg, A., Bhiman, J. N., Lessells, R. J., Moosa, M. S.,
801 Davenport, M. P., de Oliveira, T., Moore, P. L. & Sigal, A. Omicron extensively but
802 incompletely escapes Pfizer BNT162b2 neutralization. *Nature* (2021). 10.1038/s41586-021-
803 04387-1
- 804

- 805 56 Khan, K., Karim, F., Cele, S., Reedoy, K., San, J. E., Lustig, G., Tegally, H., Rosenberg, Y.,
806 Bernstein, M., Jule, Z., Ganga, Y., Ngcobo, N., Mazibuko, M., Mthabela, N., Mhlane, Z.,
807 Mbatha, N., Miya, Y., Giandhari, J., Ramphal, Y., Naidoo, T., Sivro, A., Samsunder, N.,
808 Kharsany, A. B. M., Amoako, D., Bhiman, J. N., Manickchand, N., Karim, Q. A., Magula, N.,
809 Abdool Karim, S. S., Gray, G., Hanekom, W., von Gottberg, A., Milo, R., Gosnell, B. I., Lessells,
810 R. J., Moore, P. L., de Oliveira, T., Moosa, M. S. & Sigal, A. Omicron infection enhances Delta
811 antibody immunity in vaccinated persons. *Nature* (2022). 10.1038/s41586-022-04830-x
- 812
- 813 57 Tepasse, P. R., Hafezi, W., Lutz, M., Kühn, J., Wilms, C., Wiewrodt, R., Sackarnd, J., Keller, M.,
814 Schmidt, H. H. & Vollenberg, R. Persisting SARS-CoV-2 viraemia after rituximab therapy: two
815 cases with fatal outcome and a review of the literature. *Br J Haematol* **190**, 185-188 (2020).
816 PMC7300950. 10.1111/bjh.16896
- 817
- 818 58 Thornton, C. S., Huntley, K., Berenger, B. M., Bristow, M., Evans, D. H., Fonseca, K., Franko,
819 A., Gillrie, M. R., Lin, Y. C., Povitz, M., Shafey, M., Conly, J. M. & Tremblay, A. Prolonged
820 SARS-CoV-2 infection following rituximab treatment: clinical course and response to
821 therapeutic interventions correlated with quantitative viral cultures and cycle threshold
822 values. *Antimicrob Resist Infect Control* **11**, 28 (2022). PMC8817557. 10.1186/s13756-022-
823 01067-1
- 824
- 825 59 Spiera, R., Jinich, S. & Jannat-Khah, D. Rituximab, but not other antirheumatic therapies, is
826 associated with impaired serological response to SARS- CoV-2 vaccination in patients with
827 rheumatic diseases. *Ann Rheum Dis* **80**, 1357-1359 (2021). 10.1136/annrheumdis-2021-
828 220604
- 829
- 830 60 Bonelli, M. M., Mrak, D., Perkmann, T., Haslacher, H. & Aletaha, D. SARS-CoV-2 vaccination
831 in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune
832 response. *Ann Rheum Dis* **80**, 1355-1356 (2021). 10.1136/annrheumdis-2021-220408
- 833
- 834 61 Crotty, S. A brief history of T cell help to B cells. *Nature Reviews Immunology* **15**, 185-189
835 (2015). 10.1038/nri3803
- 836
- 837 62 Clark, S. A., Clark, L. E., Pan, J., Coscia, A., McKay, L. G. A., Shankar, S., Johnson, R. I., Bruslic,
838 V., Choudhary, M. C., Regan, J., Li, J. Z., Griffiths, A. & Abraham, J. SARS-CoV-2 evolution in
839 an immunocompromised host reveals shared neutralization escape mechanisms. *Cell* **184**,
840 2605-2617 e2618 (2021). PMC7962548. 10.1016/j.cell.2021.03.027
- 841
- 842 63 Krause, R., Snyman, J., Shi-Hsia, H., Muema, D., Karim, F., Ganga, Y., Ngoepe, A., Zungu, Y.,
843 Gazy, I., Bernstein, M., Khan, K., Mazibuko, M., Mthabela, N., Ramjit, D., Limbo, O., Jardine,
844 J., Sok, D., Wilson, I. A., Hanekom, W., Sigal, A., Kløverpris, H., Ndung'u, T. & Leslie, A. HIV
845 skews the SARS-CoV-2 B cell response toward an extrafollicular maturation pathway. *Elife* **11**
846 (2022). 10.7554/eLife.79924
- 847
- 848 64 Fujita, S., Uriu, K., Pan, L., Nao, N., Tabata, K., Kishimoto, M., Itakura, Y., Sawa, H., Kida, I.,
849 Tamura, T., Fukuhara, T., Ito, J., Matsuno, K. & Sato, K. Impact of imprinted immunity
850 induced by mRNA vaccination in an experimental animal model. *J Infect Dis* (2023).
851 10.1093/infdis/jiad230

- 852
853 65 de Gier, B., Huiberts, A. J., Hoeve, C. E., den Hartog, G., van Werkhoven, H., van Binnendijk,
854 R., Hahné, S. J. M., de Melker, H. E., van den Hof, S. & Knol, M. J. Effects of COVID-19
855 vaccination and previous infection on Omicron SARS-CoV-2 infection and relation with
856 serology. *Nature Communications* **14**, 4793 (2023). 10.1038/s41467-023-40195-z
- 857
858 66 Khan, K., Karim, F., Ganga, Y., Bernstein, M., Jule, Z., Reedoy, K., Cele, S., Lustig, G., Amoako,
859 D., Wolter, N., Samsunder, N., Sivro, A., San, J. E., Giandhari, J., Tegally, H., Pillay, S., Naidoo,
860 Y., Mazibuko, M., Miya, Y., Ngcobo, N., Manickchund, N., Magula, N., Karim, Q. A., von
861 Gottberg, A., Abdool Karim, S. S., Hanekom, W., Gosnell, B. I., Lessells, R. J., de Oliveira, T.,
862 Moosa, M. S. & Sigal, A. Omicron BA.4/BA.5 escape neutralizing immunity elicited by BA.1
863 infection. *Nat Commun* **13**, 4686 (2022). PMC9364294. 10.1038/s41467-022-32396-9
- 864
865 67 Cele, S., Gazy, I., Jackson, L., Hwa, S. H., Tegally, H., Lustig, G., Giandhari, J., Pillay, S.,
866 Wilkinson, E., Naidoo, Y., Karim, F., Ganga, Y., Khan, K., Bernstein, M., Balazs, A. B., Gosnell,
867 B. I., Hanekom, W., Moosa, M. S., Network for Genomic Surveillance in South, A., Team, C.-
868 K., Lessells, R. J., de Oliveira, T. & Sigal, A. Escape of SARS-CoV-2 501Y.V2 from neutralization
869 by convalescent plasma. *Nature* **593**, 142-146 (2021). 10.1038/s41586-021-03471-w
- 870
871
872

873 Figure Legends

874 **Figure 1: Persistent SARS-CoV-2 infection and accumulation of mutations in advanced**
875 **HIV disease immunosuppression.** A) SARS-CoV-2 infection through time in five participants
876 with advanced HIV disease. X-axis represents infection period and bar above each graph
877 represents the timing of the infection waves for each variant/strain in South Africa. Y-axis
878 represents the qPCR cycle threshold (Ct) value, inversely proportional to the SARS-CoV-2
879 viral titer, as detected in the combined nasopharyngeal and oropharyngeal swab. Red circles
880 represent successfully sequenced timepoints and vertical dashed lines represent Pfizer
881 BNT162b2 mRNA vaccination times. B) HIV viral loads for the participants measured in the
882 blood as RNA copies/mL. Green bars above graphs denote periods of adherence to
883 dolutegravir (DTG) based ART. C) Phylogenetic tree of the sequenced virus samples through
884 time for each participant (27: grey circles, 96: purple circles, 127: purple triangles, 127: blue
885 circles, 209: green circles). X-axis represents distance in mutations from ancestral clade 20A
886 SARS-CoV-2. Tree generated using Nextclade (<https://clades.nextstrain.org/>).

887 **Figure 2: SARS-CoV-2 clearance in advanced HIV disease immunosuppression**
888 **associates with emergence of a neutralizing antibody response.** A) SARS-CoV-2 titers
889 measured as qPCR Ct through time until SARS-CoV-2 clearance for participants 27, 96, 127,
890 255, and 209. Clearance defined as two consecutive timepoints where SARS-CoV-2 was not
891 detected. X-axis is time in days post-SARS-CoV-2 diagnosis and is the same in all panels
892 which describe the same participant. Y-axis is SARS-CoV-2 titer as Ct value. B) Antibody
893 neutralization of SARS-CoV-2 isolated from each participant. One to two autologous viruses
894 were tested per participant and are indicated on the top left of each graph by the day of
895 isolation (denoted by a D prefix) post-diagnosis. Numbers above bars are geometric means
896 and error bars indicate geometric mean standard deviations of 2-4 independent experiments.
897 C) HIV viral load in the blood during the period of SARS-CoV-2 infection. D) CD4 T cell
898 concentrations during the period of SARS-CoV-2 infection. Horizontal lines represent limits of
899 quantification in all panels.

900 **Figure 3: Advanced HIV disease participants with unsuppressed viremia have a poor**
901 **vaccine response.** A) Longitudinal neutralization and anti-spike antibody levels before and
902 after vaccination with the Pfizer BNT162b2 mRNA vaccine in the three advanced HIV disease
903 participants who suppressed HIV at vaccination (27, 96, 127) and the two who did not (255,
904 209). Neutralization was tested against ancestral/D614G SARS-CoV-2 (grey), Beta variant
905 (purple), Delta variant (blue), and Omicron BA.1 subvariant (green). Timing of vaccine doses
906 is represented by vertical dashed lines. X-axis is time in days post-first vaccine dose and
907 negative numbers represent pre-vaccine period. Left Y-axis is neutralization capacity per viral
908 isolate as FRNT₅₀ and right Y-axis is anti-spike antibody level as arbitrary units (AU). B)
909 Longitudinal neutralization and anti-spike antibody levels before and after vaccination in five
910 participants with no advanced HIV disease. C) Neutralization of SARS-CoV-2 D614G, Beta,
911 Delta and Omicron BA.1 viral isolates pre-vaccination and after last administered dose by
912 plasma from the two participants with advanced HIV disease and HIV viremia (marked with
913 red lines), the three participants with advanced HIV disease and HIV suppression (green lines)
914 and 26 participants with no advanced HIV disease (grey lines). Y-axis is neutralization as
915 FRNT₅₀. Numbers above groups are geometric means and statistical comparison is between
916 participant FRNT₅₀ values before and after vaccination and are all ****p<0.0001 by the Mann-
917 Whitney test.

918

919 **Figure 4: Antigenic distances of SARS-CoV-2 evolved from ancestral and Delta**
920 **infections in the hamster model.** A) Substitutions and deletions in the N-terminal domain
921 (NTD) and receptor binding domain (RBD) of SARS-CoV-2 spike in 27-D190 and 255-D237.
922 Blue mutations: known antibody escape. Red mutations: mutations with global prevalence
923 below 0.01%. RBM: receptor binding motif. Representation and characterization based on the
924 Stanford Coronavirus Antiviral and Resistance Database (<https://covdb.stanford.edu>). B)
925 Schematic of hamster infection experiment. Six animals in two independent experiments were
926 used per infection condition. C) Neutralization of ancestral D614G, 27-D190, 255-D237, and
927 Omicron XBB.1.5 subvariant viruses in uninfected hamsters. D-G) Neutralization of the same
928 viruses at 16 days post-infection in hamsters infected with ancestral/D614G (D), 27-D190 (E),
929 255-D237 (F), and the XBB.1.5 subvariant (G). Numbers above the points and horizontal bars
930 are geometric means for the group. Significance was determined by the Mann-Whitney test
931 relative to the autologous (infecting) virus. Significant p-values from left to right were: 0.03,
932 0.002, 0.002, 0.009, 0.002, 0.009, 0.002, 0.002, 0.002, 0.002, 0.002. H) Antigenic map of
933 neutralization data presented in panels D-G. Virus strains/variants are shown as colored
934 circles and hamster plasma samples as open squares with the color corresponding to the virus
935 strain or variant used to infect the hamster. Each square on the grid correspond to a twofold
936 decrease in neutralizing capacity. Map created using Racmacs
937 (<https://acorg.github.io/Racmacs/>). Parts of panel B created with BioRender.com.

938 **Figure 5: Neutralization of Delta evolved virus by participants with Delta and Omicron**
939 **infection elicited immunity.** A) Neutralization of the 255-D237 virus compared to the Delta
940 variant virus by plasma samples from 10 participants infected during the Delta variant infection
941 wave in South Africa. B) Neutralization of the 255-D237 virus compared to the Omicron BA.1
942 subvariant virus in plasma samples from 24 participants infected with Omicron BA.1. FRNT₅₀
943 for one participant was out of the range of the graph but included in the calculation of the
944 geometric mean. C) Neutralization of 255-D237 compared to Omicron BA.1 virus in plasma
945 samples from 15 vaccinated participants with Omicron BA.1 breakthrough infection. D)
946 Neutralization of the 255-D237 compared to the Omicron XBB.1.5 subvariant virus in plasma
947 samples from 8 participants infected when XBB subvariants were dominant in South Africa.
948 All samples were collected approximately 2 to 3 weeks post-diagnosis in the corresponding
949 infection period. The numbers above the points and horizontal bars are geometric means of
950 the group and p-values were determined by the Mann-Whitney test and were: ****p<0.0001,
951 *p=0.03.

952 **Figure S1: Antiretroviral drugs detected in plasma samples from the 5 participants with**
953 **advanced HIV disease.** ART components assayed by LC-MS/MS were the integrase inhibitor
954 dolutegravir (DTG), the nucleotide reverse transcriptase inhibitor tenofovir (TFV), the
955 nucleoside reverse transcriptase inhibitors emtricitabine (FTC), lamivudine (3TC), abacavir
956 (ABC), and azidothymidine (AZT), the nonnucleoside reverse transcriptase inhibitors
957 Efavirenz (EFV) and nevirapine (NVP), and the protease inhibitors lopinavir (LPV), ritonavir
958 (RTV), atazanavir (ATV) and darunavir (DRV). X-axis is participant study visit and y-axis is
959 HIV viral load as RNA copies/mL (above) or antiretroviral drug (below). Green or blue
960 rectangles indicate the corresponding drug was detected at the timepoint at a level above 3
961 ng/mL, the limit of detection. Green rectangles indicate the presence of components of the
962 regimen of TFV, 3TC, and DTG on which participants were initiated, and blue rectangles
963 indicate components of other regimens.

964 **Figure S2: Substitutions or deletions in SARS-CoV-2 sequences of advanced HIV**
965 **disease participants through time.** Horizontal axis indicates the SARS-CoV-2 protein where
966 substitution or deletion occurred relative to the infecting strain and vertical axis is the time

967 post-diagnosis the viral isolate was obtained. Analysis performed using the Stanford
968 Coronavirus Antiviral and Resistance Database (<https://covdb.stanford.edu>).

969 **Figure S3: Neutralizing antibody response of participant plasma against autologous**
970 **outgrown virus at different timepoints.** Representative image showing infection foci in wells
971 of a multi-well plate from a live virus focus forming assay of participant 209 plasma against
972 autologous virus (209-D5). Plasma samples were from timepoints pre-SARS-CoV-2 clearance
973 (D37, D110, D123) through to clearance (D187). Columns are plasma dilutions which range
974 from 1:10 to 1:1280 and rows are plasma timepoint used. Bar is 2mm.




Figure 1: Persistent SARS-CoV-2 infection and accumulation of mutations in advanced HIV disease immunosuppression. (A) SARS-CoV-2 infection through time in five participants with advanced HIV disease. X-axis represents infection period and bar above each graph represents the timing of the infection waves for each variant/strain in South Africa. Y-axis represents the qPCR cycle threshold (Ct) value, inversely proportional to the SARS-CoV-2 viral titer, as detected in the combined nasopharyngeal and oropharyngeal swab. Red circles represent successfully sequenced timepoints and vertical dashed lines represent Pfizer BNT162b2 mRNA vaccination times. B) HIV viral loads for the participants measured in the blood as RNA copies/mL. Green bars above graphs denote periods of adherence to dolutegravir (DTG) based ART. C) Phylogenetic tree of the sequenced virus samples through time for each participant (27: grey circles, 96: purple circles, 127: purple triangles, 127: blue circles, 209: green circles). X-axis represents distance in mutations from ancestral clade 20A SARS-CoV-2. Tree generated using Nextclade (<https://clades.nextstrain.org/>).




Figure 2: SARS-CoV-2 clearance in advanced HIV disease immunosuppression associates with emergence of a neutralizing antibody response. A) SARS-CoV-2 titers measured as qPCR Ct through time until SARS-CoV-2 clearance for participants 27, 96, 127, 255, and 209. Clearance defined as two consecutive timepoints where SARS-CoV-2 was not detected. X-axis is time in days post-SARS-CoV-2 diagnosis and is the same in all panels which describe the same participant. Y-axis is SARS-CoV-2 titer as Ct value. B) Antibody neutralization of SARS-CoV-2 isolated from each participant. One to two autologous viruses were tested per participant and are indicated on the top left of each graph by the day of isolation (denoted by a D prefix) post-diagnosis. Numbers above bars are geometric means and error bars indicate geometric mean standard deviations of 2-4 independent experiments. C) HIV viral load in the blood during the period of SARS-CoV-2 infection. D) CD4 T cell concentrations during the period of SARS-CoV-2 infection. Horizontal lines represent limits of quantification in all panels.




Figure 3: Advanced HIV disease participants with unsuppressed viremia have a poor vaccine response. A) Longitudinal neutralization and anti-spike antibody levels before and after vaccination with the Pfizer BNT162b2 mRNA vaccine in the three advanced HIV disease participants who suppressed HIV at vaccination (27, 96, 127) and the two who did not (255, 209). Neutralization was tested against ancestral/D614G SARS-CoV-2 (grey), Beta variant (purple), Delta variant (blue), and Omicron BA.1 subvariant (green). Timing of vaccine doses is represented by vertical dashed lines. X-axis is time in days post-first vaccine dose and negative numbers represent pre-vaccine period. Left Y-axis is neutralization capacity per viral isolate as $FRNT_{50}$ and right Y-axis is anti-spike antibody level as arbitrary units (AU). B) Longitudinal neutralization and anti-spike antibody levels before and after vaccination in five participants with no advanced HIV disease. C) Neutralization of SARS-CoV-2 D614G, Beta, Delta and Omicron BA.1 viral isolates pre-vaccination and after last administered dose by plasma from the two participants with advanced HIV disease and HIV viremia (marked with red lines), the three participants with advanced HIV disease and HIV suppression (green lines) and 26 participants with no advanced HIV disease (grey lines). Y-axis is neutralization as $FRNT_{50}$. Numbers above groups are geometric means and statistical comparison is between participant $FRNT_{50}$ values before and after vaccination and are all ****p < 0.0001 by the Mann-Whitney test.




Figure 4: Antigenic distances of SARS-CoV-2 evolved from ancestral and Delta infections in the hamster model. A) Substitutions and deletions in the N-terminal domain (NTD) and receptor binding domain (RBD) of SARS-CoV-2 spike in 27-D190 and 255-D237. Blue mutations: known antibody escape. Red mutations: mutations with global prevalence below 0.01%. RBM: receptor binding motif. Representation and characterization based on the Stanford Coronavirus Antiviral and Resistance Database (<https://covdb.stanford.edu>). B) Schematic of hamster infection experiment. Six animals in two independent experiments were used per infection condition. C) Neutralization of ancestral D614G, 27-D190, 255-D237, and Omicron XBB.1.5 subvariant viruses in uninfected hamsters. D-G) Neutralization of the same viruses at 16 days post-infection in hamsters infected with ancestral/D614G (D), 27-D190 (E), 255-D237 (F), and the XBB.1.5 subvariant (G). Numbers above the points and horizontal bars are geometric means for the group. Significance was determined by the Mann-Whitney test relative to the autologous (infecting) virus. Significant p-values from left to right were: 0.03, 0.002, 0.002, 0.009, 0.002, 0.009, 0.002, 0.002, 0.002, 0.002, 0.002. H) Antigenic map of neutralization data presented in panels D-G. Virus strains/variants are shown as colored circles and hamster plasma samples as open squares with the color corresponding to the virus strain or variant used to infect the hamster. Each square on the grid correspond to a twofold decrease in neutralizing capacity. Map created using Racmacs (<https://acorg.github.io/Racmacs/>). Parts of panel B created with BioRender.com.




Figure 5: Neutralization of Delta evolved virus by participants with Delta and Omicron infection elicited immunity. A) Neutralization of the 255-D237 virus compared to the Delta variant virus by plasma samples from 10 participants infected during the Delta variant infection wave in South Africa. B) Neutralization of the 255-D237 virus compared to the Omicron BA.1 subvariant virus in plasma samples from 24 participants infected with Omicron BA.1. $FRNT_{50}$ for one participant was out of the range of the graph but included in the calculation of the geometric mean. C) Neutralization of 255-D237 compared to Omicron BA.1 virus in plasma samples from 15 vaccinated participants with Omicron BA.1 breakthrough infection. D) Neutralization of the 255-D237 compared to the Omicron XBB.1.5 subvariant virus in plasma samples from 8 participants infected when XBB subvariants were dominant in South Africa. All samples were collected approximately 2 to 3 weeks post-diagnosis in the corresponding infection period. The numbers above the points and horizontal bars are geometric means of the group and p-values were determined by the Mann-Whitney test and were: **** $p < 0.0001$, * $p = 0.03$.






Figure S1: Antiretroviral drugs detected in plasma samples from the 5 participants with advanced HIV disease. ART components assayed by LC-MS/MS were the integrase inhibitor dolutegravir (DTG), the nucleotide reverse transcriptase inhibitor tenofovir (TFV), the nucleoside reverse transcriptase inhibitors emtricitabine (FTC), lamivudine (3TC), abacavir (ABC), and zidovudine (AZT), the nonnucleoside reverse transcriptase inhibitors efavirenz (EFV) and nevirapine (NVP), and the protease inhibitors lopinavir (LPV), ritonavir (RTV), atazanavir (ATV) and darunavir (DRV). X-axis is participant study visit and y-axis is HIV viral load as RNA copies/mL (above) or antiretroviral drug (below). Green or blue rectangles indicate the corresponding drug was detected at the timepoint at a level above 3 ng/mL, the limit of detection. Green rectangles indicate the presence of components of the regimen of TFV, 3TC, and DTG on which participants were initiated, and blue rectangles indicate components of other regimens.


Participant 27




Participant 96



Participant 127



Participant 255



Participant 209




Figure S2: Substitutions or deletions in SARS-CoV-2 sequences of advanced HIV disease participants through time. Horizontal axis indicates the SARS-CoV-2 protein where substitution or deletion occurred relative to the infecting strain and vertical axis is the time post-diagnosis the viral isolate was obtained. Analysis performed using the Stanford Coronavirus Antiviral and Resistance Database (<https://covdb.stanford.edu>).




Figure S3: Neutralizing antibody response of participant plasma against autologous out-grown virus at different timepoints. Representative image showing infection foci in wells of a multi-well plate from a live virus focus forming assay of participant 209 plasma against autologous virus (209-D5). Plasma samples were from timepoints pre-SARS-CoV-2 clearance (D37, D110, D123) through to clearance (D187). Columns are plasma dilutions which range from 1:10 to 1:1280 and rows are plasma timepoint used. Bar is 2mm.

Table S1: Participants enrolled in the study

	All 994	HIV- n=587 (59%)	HIV Suppressed* CD4** >200 n=259 (26%)	HIV viremic CD4** >200 n=35 (4%)	HIV viremic/suppressed CD4** <200 n=113 (11%)
Age (median, IQR)	41 (32-52)	42 (31-55)	42 (35-50)	34.5 (27-38)	41 (32-47)
Female	621 (62%)	347 (59%)	193 (75%)	22 (63%)	59 (52%)
SuppO2	143 (14%)	62 (11%)	36 (14%)	8 (23%)	37 (33%)
CD4 count (median, IQR)	774.5 (467-1035)	907.5 (676-1149)	695 (478-901.5)	433 (283-540)	65 (23-134)
Vaccination: Current Status of Study					
Not vaccinated	493 (50%)	253 (43%)	127 (49%)	24 (69%)	89 (79%)
1 dose BNT162b2***	32 (3%)	18 (3%)	10 (4%)	1 (3%)	3 (3%)
1 dose Ad26.COV2.S	281 (28%)	210 (36%)	59 (23%)	6 (17%)	6 (5%)
2 doses BNT162b2	188 (19%)	106 (18%)	63 (24%)	4 (11%)	15 (13%)
Variant#:					
Ancestral	147 (15%)	86 (14%)	44 (17%)	8 (23%)	9 (8%)
Beta	135 (13%)	92 (16%)	24 (9%)	4 (11%)	15 (13%)
Delta	106 (11%)	52 (9%)	32 (12%)	3 (9%)	19 (16%)
Omicron BA.1, BA.2	97 (10%)	51 (9%)	23 (9%)	3 (9%)	20 (18%)
Omicron BA.5 related	53 (5%)	22 (4%)	14 (6%)	4 (11%)	13 (12%)
Omicron XBB	96 (10%)	65 (11%)	21 (8%)	2 (6%)	8 (7%)
No infection (controls)	360 (36%)	219 (37%)	101 (39%)	11 (31%)	29 (26%)
Comorbidities:					
Diabetes	108 (11%)	77 (13%)	26 (10%)	1 (3%)	4 (4%)
Hypertension	199 (20%)	129 (22%)	57 (22%)	4 (11%)	9 (8%)
Cardiovascular Disease	30 (3%)	25 (4%)	3 (1%)	0 (0%)	2 (2%)

*Median HIV viral load < 500. **Median CD4 count. ***At enrollment. #Variant determined by dominant circulating variant at enrollment.

Table S2: Participants with advanced HIV disease in the study

Participant	Sex	Age range	Diagnosis	Infect. wave	Enrol. CD4	Enrol. HIV VL	1 st Vacc. Date	Vacc. CD4	Vacc. HIV VL	Time to last positive
27	F	30-39	Sep 2020	D614G	6	34151	Sep 2021	92	40	215
96	M	40-49	Apr 2021	Beta	4	111883	Nov 2021	59	40	110
127	M	30-39	Mar 2021	Beta	12	8581	Sep 2021	120	40	207
209	F	30-29	Dec 2021	Omicron	24	423817	Apr 2022	31	661666	165
255	M	20-29	Sep 2021	Delta	2	12041	Jun-2022	42	17813	289

Table S3: Pfizer-vaccinated longitudinally tracked participant controls

Participant	Sex	Age range	Diagnosis	Infect. wave	Enrol. CD4	Enrol. HIV VL	1 st Vacc. Date	Vacc. CD4	Vacc. HIV VL	Time to last positive
9	F	40-49	Jun 2020	D614G	706	<40	Sep 2021	658	<40	25
21	F	30-39	Jul 2020	D614G	663	<40	Sep 2021	815	<40	9
69	F	40-49	Aug 2020	D614G	702	<40	Sep 2021	757	<40	11
123	F	20-29	Feb 2021	Beta	1551	-	Sep 2021	686	-	5
149	F	50-59	Jul 2021	Delta	211	-	Sep 2021	935	-	2

Table S4: Summary vaccinated participants (no advanced HIV disease)

	All (n=26)	HIV- (n=16)	PLWH (n=10)
Female	17 (65%)	11 (69%)	6 (60%)
Age (median, IQR)		42.5 (31-63)	47 (41-55)
Infecting Variant by Date			
Ancestral	16 (62%)	10 (63%)	6 (60%)
Beta	6 (23%)	4 (25%)	2 (20%)
Delta	4 (15%)	2 (13%)	2 (20%)
Vacc. CD4 (median, IQR)	830.5 (686-1003)	948 (765-1184.5)	707.5 (464-815)
Vacc. HIV VL (median, IQR)	-	-	40 (40-40)
Last dose to sample (median, IQR days)	24.5 (14-29)	27.5 (19-29.5)	15.5 (13-28)

Table S5: Participants from different infection periods

	Delta* n=10	BA.1 unvaccinated n=24	BA.1 vaccinated n=15	XBB unvaccinated n=8
Female	2 (20%)	16 (67%)	9 (60%)	5 (63%)
Age (median, IQR)	47 (41-56)	31.5 (26-49)	37 (32-60)	53 (37.5-67.5)
CD4 (median, IQR)	938 (671-1238)	772 (611-1055.5)	679 (584-904)	925 (723-1102)
HIV Positive	4 (40%)	8 (33%)	4 (27%)	2 (25%)
Diagnosis to sample (median, IQR days)	23 (22-26)	21.5 (17-26.5)	22 (17-23)	13 (9-17)
Last dose to sample (median, IQR days)	23 (21-31)	-	168 (148-220)	-

*Two participants vaccinated with 1 dose BNT162b2. Delta enrollments from 01 June 2021-31 Oct 2021. Omicron BA.1 enrollments from 01 Nov 2021-28 Feb 2022. Omicron BA.4/5 enrollments from 01 Mar 2022-31 Oct 2022. Omicron XBB enrollments from 01 Nov 2022-01 Jun 2023.